Health Care Closes Flat Amid Pipeline Deals and Company Updates

On Friday, October 2, the Health Care Select Sector SPDR Fund, an exchange-traded fund tracking the sector under the ticker XLV, closed at 0.0% to settle at $166.15. Across the sector, 54.5% of member stocks advanced, yielding an equal-weighted change of +0.1%, while the cap-weighted sector finished at 0.0%. Inside the portfolio, where companies graded A or B account for 52.5% of the fund's graded weight, Centene Corp led with +3.3% and Humana Inc posted +2.3%, while Veeva Systems Inc Class A registered -3.1%. The quiet session coincided with multi-billion-dollar licensing agreements and regulatory updates across several major pharmaceutical companies.

Major pharmaceutical companies announced new multi-billion-dollar development pacts during the session. Sanofi and Regeneron expanded their immunology collaboration, with Regeneron securing a $1 billion upfront payment and potential milestones reaching up to $7 billion to develop four next-generation antibodies. In another large transaction, Novartis agreed to an exclusive worldwide license with Abogen for RNA-platform programs in a deal potentially worth up to $7.2 billion, including $575 million upfront.

Drug pricing frameworks and clinical trial readouts also drew attention. AbbVie agreed to join a federal pilot program beginning in 2027 to evaluate a new rebate model for discounted medicines under the 340B drug pricing program. In clinical news, Biogen reported 52-week trial results from its mid-stage study of litifilimab for cutaneous lupus erythematosus, showing durable reductions in skin disease activity.

While XLV sits at -3.9% over the past month, the fund stands at +13.9% over the past 100 sessions and +16.0% over the past twelve months. That broader stability provides context for the sector as individual drugmakers manage commercial agreements, pipeline transitions, and federal pricing initiatives.